Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2013

View Archived Issues

Servier partners with SIgN for immunomodulatory drugs

Sanofi's Complavin combination tablets approved in Japan

Stanford University presents 64Cu-NOTA-B-Fab, an immuno-PET tracer companion diagnostic

Proximagen begins phase II PRX-167700 study of knee osteoarthritis

Phase III study of BioMarin's BMN-673 in metastatic breast cancer commences

Bioheart forms license agreement with Invitrx

Cornerstone Pharmaceuticals begins phase II CPI-613 trial in MDS

Torrent Pharmaceuticals presents first clinical data for TRC-150094

Gemigliptin is safe and efficient as a long-term treatment added to ongoing metformin

DatSCAN intravenous injection approved in Japan

Ablynx and Merck Serono expand nanobodies partnership

Program to evaluate LUM-001 in Alagille syndrome, FDA grants LUM-001 orphan drug designations

Merck KGaA to renew testing of lung cancer vaccine

Tetra Discovery receives phase II SBIR grant to develop new depression drug

Bio-Matrix Scientific provides update on dCellVax for breast cancer

Novo Nordisk files application to expand approval of liraglutide in Japan

Mologen submits MGN-1703 IND application with FDA

Simeprevir obtains first approval in Japan

CSL Behring gains Japanese approval for Hizentra

Alnylam Pharmaceuticals reports interim results from phase I ALN-TTRsc trial

Experimental LTC4S gene overexpression replicates aspirin-induced asthma

TNF-alpha production inhibitors reported by PuraPharm and Versitech

Lupin discovers nAChR alpha7 modulators

Cadila Healthcare divulges discovery of PCSK9 inhibitors

Merck & Co. prepares and tests novel PAR-1 antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...